Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1994 5
1995 8
1996 4
1997 12
1998 7
1999 8
2000 4
2001 8
2002 8
2003 12
2004 24
2005 9
2006 11
2007 16
2008 26
2009 18
2010 18
2011 38
2012 43
2013 52
2014 32
2015 57
2016 53
2017 46
2018 60
2019 36
2020 50
2021 52
2022 36
2023 50
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

736 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC. ...
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a s …
Therapeutic strategies targeting folate receptor alpha for ovarian cancer.
Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J, Li Q. Mai J, et al. Front Immunol. 2023 Aug 30;14:1254532. doi: 10.3389/fimmu.2023.1254532. eCollection 2023. Front Immunol. 2023. PMID: 37711615 Free PMC article. Review.
Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment options. Folate receptor alpha (FRalpha), encoded by the FOLR1 gene, is an attractive therapeutically target due to …
Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment opti …
IMGN853, a Folate Receptor-alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors.
Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM. Ab O, et al. Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22. Mol Cancer Ther. 2015. PMID: 25904506
A majority of ovarian and non-small cell lung adenocarcinoma cancers overexpress folate receptor alpha (FRalpha). Here, we report the development of an anti-FRalpha antibody-drug conjugate (ADC), consisting of a FRalpha-binding antibody attached to a highly p …
A majority of ovarian and non-small cell lung adenocarcinoma cancers overexpress folate receptor alpha (FRalpha). Here, …
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM. Gilbert L, et al. Gynecol Oncol. 2023 Mar;170:241-247. doi: 10.1016/j.ygyno.2023.01.020. Epub 2023 Feb 1. Gynecol Oncol. 2023. PMID: 36736157 Free article.
METHODS: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was 6 months, were administered mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, on …
METHODS: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval …
Mirvetuximab Soravtansine: First Approval.
Heo YA. Heo YA. Drugs. 2023 Feb;83(3):265-273. doi: 10.1007/s40265-023-01834-3. Drugs. 2023. PMID: 36656533 Review.
Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere()) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor alpha (FRalpha) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. The ADC is being …
Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere()) is an antibody-drug conjugate (ADC), which is comprised of a folate …
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Nishikawa T, Shimoi T, Sudo K, Saito A, Okuma HS, Tanioka M, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Ohe Y, Yonemori K. Yazaki S, et al. J Gynecol Oncol. 2022 Nov;33(6):e82. doi: 10.3802/jgo.2022.33.e82. Epub 2022 Sep 27. J Gynecol Oncol. 2022. PMID: 36245230 Free PMC article.
OBJECTIVE: Folate receptor alpha (FRalpha) is a membrane protein expressed in various solid tumors but has limited expression in normal cells. ...CONCLUSION: In cervical cancer, FRalpha expression was elevated in metastatic tumors and hig …
OBJECTIVE: Folate receptor alpha (FRalpha) is a membrane protein expressed in various solid tumors but has limit …
Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck.
Schnoell J, Jank BJ, Kadletz-Wanke L, Stoiber S, Gurnhofer E, Schlederer M, Heiduschka G, Kenner L. Schnoell J, et al. Onco Targets Ther. 2022 May 16;15:531-538. doi: 10.2147/OTT.S351500. eCollection 2022. Onco Targets Ther. 2022. PMID: 35601979 Free PMC article.
PURPOSE: Folate receptor alpha (FRalpha) is overexpressed in various cancer entities while expression in normal tissue is limited. ...CONCLUSION: FRalpha expression is common in ACC of the head and neck. Therefore, FRalpha should be further eval …
PURPOSE: Folate receptor alpha (FRalpha) is overexpressed in various cancer entities while expression in normal …
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R. Ponte JF, et al. Neoplasia. 2016 Dec;18(12):775-784. doi: 10.1016/j.neo.2016.11.002. Epub 2016 Nov 25. Neoplasia. 2016. PMID: 27889646 Free PMC article.
Elevated folate receptor alpha (FRalpha) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. ...
Elevated folate receptor alpha (FRalpha) expression is characteristic of epithelial ovarian cancer (EOC), thus e …
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. O'Malley DM, et al. Gynecol Oncol. 2020 May;157(2):379-385. doi: 10.1016/j.ygyno.2020.01.037. Epub 2020 Feb 18. Gynecol Oncol. 2020. PMID: 32081463 Clinical Trial.
PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRalpha) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-target …
PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti- …
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor alpha (FRalpha), is approved for the treatment of platinum-resistant ovarian cancer in the United States. ...Participants who had previously …
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor alpha …
736 results